Pentoxifylline in hepatopulmonary syndrome

Area of Science:

• Pediatric Gastroenterology
• Pulmonology
• Pharmacology

Background:

• Hepatopulmonary syndrome (HPS) is a serious complication of chronic liver disease in children.
• HPS is characterized by impaired gas exchange, leading to hypoxemia.
• Current treatment options for pediatric HPS are limited.

Purpose of the Study:

• To investigate the efficacy of pentoxifylline (PTX) in improving clinical manifestations and arterial blood gas parameters in pediatric HPS.
• To evaluate the safety and tolerability of PTX in this patient population.

Main Methods:

• A pilot study involving 10 children with chronic liver disease and HPS.
• Administration of pentoxifylline (PTX) at 20 mg/kg/d for 3 months.
• Evaluation of clinical data and arterial blood gas parameters at baseline, end of treatment, and 3 months post-discontinuation.

Main Results:

• Six out of ten patients tolerated PTX; four experienced complications.
• In tolerant patients, significant improvements were observed in arterial oxygen pressure (PaO2) and oxygen saturation (SaO2).
• The alveolar-arterial oxygen gradient significantly improved with PTX treatment and showed a significant decrease after drug discontinuation.

Conclusions:

• Pentoxifylline (PTX) demonstrates potential as a therapeutic agent for early-stage hepatopulmonary syndrome in children.
• PTX may improve key indicators of gas exchange, including PaO2, SaO2, and the alveolar-arterial oxygen gradient.
• Further research is warranted to confirm these findings and establish optimal treatment protocols.